Browsing by 저자 : Howard Gurney
전체 결과 7건 중 1-7 번을 표시중입니다.
-
1
Article
Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region
Masatoshi Eto
;
Jae-Lyun Lee
;
Yen-Hwa Chang
;
et al
2022
-
2
Article
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
이재련
;
Andre P Fay
;
Andrea Necchi
;
et al
2020
-
3
Article
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
Sun Young Rha
;
Toni K Choueiri
;
Vsevolod B Matveev
;
et al
2023
-
4
Article
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/ 3 mRNA Expression
Cora N Sternberg
;
Daniel P Petrylak
;
Joaquim Bellmunt
;
et al
2023
-
5
Article
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Laurence Albiges
;
Howard Gurney
;
Vagif Atduev
;
et al
2023
-
6
Article
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles
;
Piotr Tomczak
;
Se Hoon Park
;
et al
2022
-
7
Article
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt
;
Ronald de Wit
;
Yves Fradet
;
et al
2022